Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 8/20 | 0.34 |
| ▸ | MMP3 | P08254 | 4/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718536 | 1.00 | L3MBTL1 (0.38) | L3MBTL1TDP2ALDH1A1KMT2APOLB | |
| SCHEMBL2194255 | 0.84 | CRBN (0.41) | TDP2ALDH1A1KMT2A | |
| SCHEMBL2196984 | 0.82 | MEN1 (0.43) | TDP2KMT2APOLBMAPK1MMP8 | |
| SCHEMBL2196992 | 0.82 | MEN1 (0.43) | TDP2KMT2APOLBMAPK1MMP8 | |
| SCHEMBL13718868 | 0.77 | DGAT1 (0.46) | — | |
| SCHEMBL2228439 | 0.77 | DGAT1 (0.46) | — | |
| SCHEMBL2178972 | 0.75 | DGAT1 (0.43) | POLB | |
| SCHEMBL2179473 | 0.75 | DGAT1 (0.43) | POLB | |
| SCHEMBL2195082 | 0.75 | MAPT (0.43) | ALDH1A1KMT2APOLB | |
| SCHEMBL13829376 | 0.71 | PRF1 (0.45) | TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | L3MBTL1 1071/4885TDP2 928/4885ALDH1A1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.